For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...
On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...
Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...
The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...
Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following ...
With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...
The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...
Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...
PR Newswire • 6 months ago Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. The addition of the Clayton site in ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Grifols SA needs to focus on financial restructuring and address corporate governance issues to win over investors after ...